ES3028538T3 - 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases - Google Patents

5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases Download PDF

Info

Publication number
ES3028538T3
ES3028538T3 ES19742480T ES19742480T ES3028538T3 ES 3028538 T3 ES3028538 T3 ES 3028538T3 ES 19742480 T ES19742480 T ES 19742480T ES 19742480 T ES19742480 T ES 19742480T ES 3028538 T3 ES3028538 T3 ES 3028538T3
Authority
ES
Spain
Prior art keywords
compound
mitochondrial
hydroxyethyl
thiazolidine
dione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES19742480T
Other languages
English (en)
Spanish (es)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Pascau Laura Pilar Rodriguez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Application granted granted Critical
Publication of ES3028538T3 publication Critical patent/ES3028538T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES19742480T 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases Active ES3028538T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06
PCT/IB2019/054696 WO2019234664A1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
ES3028538T3 true ES3028538T3 (en) 2025-06-19

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
ES19742480T Active ES3028538T3 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Country Status (13)

Country Link
US (2) US11957670B2 (https=)
EP (2) EP4545142A3 (https=)
JP (1) JP7376934B2 (https=)
DK (1) DK3801515T3 (https=)
ES (1) ES3028538T3 (https=)
FI (1) FI3801515T3 (https=)
HR (1) HRP20250591T1 (https=)
HU (1) HUE071482T2 (https=)
LT (1) LT3801515T (https=)
PL (1) PL3801515T3 (https=)
PT (1) PT3801515T (https=)
SI (1) SI3801515T1 (https=)
WO (1) WO2019234664A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
EP3917508A4 (en) 2019-01-28 2022-12-21 Mitochondria Emotion, Inc. EAAT2 ACTIVATORS AND METHODS OF USE THEREOF
CA3127453A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Trans-4-hydroxycyclohexyl phenyl amide mitofusin activators and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012205798B2 (en) 2011-01-10 2016-02-25 Takeda Pharmaceutical Company Limited Methods and drug products for treating Alzheimer's disease
EP3013371A4 (en) 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
EP3125888B1 (en) 2014-04-02 2018-05-23 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
WO2017057587A1 (ja) 2015-09-30 2017-04-06 株式会社ニコン 露光装置、フラットパネルディスプレイの製造方法、及びデバイス製造方法
WO2017083739A1 (en) * 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
EP3548026B1 (en) 2016-12-01 2021-01-20 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
EA202092954A1 (ru) 2018-06-06 2021-04-08 Минорикс Терапьютикс С.Л. Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
BR112020024917A2 (pt) 2018-06-06 2021-03-09 Minoryx Therapeutics S.L. Método de administrar uma quantidade terapeuticamente eficaz de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidina-2,4-diona

Also Published As

Publication number Publication date
PT3801515T (pt) 2025-06-11
JP2021527049A (ja) 2021-10-11
EP3801515B1 (en) 2025-04-09
HUE071482T2 (hu) 2025-08-28
HRP20250591T1 (hr) 2025-07-04
EP4545142A3 (en) 2025-06-11
FI3801515T3 (fi) 2025-05-27
EP4545142A2 (en) 2025-04-30
US20210228559A1 (en) 2021-07-29
SI3801515T1 (sl) 2025-07-31
JP7376934B2 (ja) 2023-11-09
US11957670B2 (en) 2024-04-16
PL3801515T3 (pl) 2025-07-14
WO2019234664A1 (en) 2019-12-12
LT3801515T (lt) 2025-06-10
DK3801515T3 (da) 2025-04-28
US20250064791A1 (en) 2025-02-27
EP3801515A1 (en) 2021-04-14

Similar Documents

Publication Publication Date Title
US11427588B2 (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
US10793514B2 (en) Glutamine transport inhibitors and methods for treating cancer
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
ES2993833T3 (en) Migalastat for use in methods of treating fabry disease in patients having a mutation in the gla gene
US20140241990A1 (en) Methods of using adenosine a1 receptor activation for treating depression
ES2973215T3 (es) Agente terapéutico para la esclerosis lateral amiotrófica y composición para el tratamiento
PT2275108E (pt) Preparação farmacêutica que compreende inibidor de dpp-iv e outro agente terapêutico de diabetes na forma concomitante ou combinada
CN113813387A (zh) Ppar激动剂在制备治疗急性髓细胞白血病的药物中的应用
ES2867300T3 (es) 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-tiazolidin-2,4-diona para tratamiento de enfermedad de hígado graso no alcohólico
US20080027052A1 (en) Methods for treating cystic kidney disease
JP2017520553A (ja) 加齢関連症状及び疾患を治療するためのケト酪酸化合物ならびに組成物
CA3102407A1 (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
AU2019247871A1 (en) Compositions and methods for increasing remyelination
JP5781077B2 (ja) ダウン症を治療するための方法および薬学的組成物
US20220226340A1 (en) Casein kinase 1 inhibitors for use in the treatment of diseases related to dux4 expression such as muscular dystrophy and cancer
ES2610362T3 (es) Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
JP2009078977A (ja) 心筋の小胞体ストレス抑制剤
US20140178456A1 (en) Methods and compositions for treating type 2 diabetes and related conditions
EA047277B1 (ru) Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона
CN110869044A (zh) 肽和用肽治疗营养不良相关病症的方法
CN121102486A (zh) 含gls1抑制剂和ampk激活剂的药物组合物及其用途
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
BR102016021058A2 (pt) composições de compostos orgânicos de selênio e métodos de uso das mesmas